SECONDARY MYELOFIBROSIS

This study is testing a combination of drugs to see if it can better prepare patients with advanced blood cancers for a stem cell transplant from a donor. The goal is to control the aggressive cancer cells before the transplant, which may help the new donor cells take hold and fi…

This study is testing whether adding a new drug called iadademstat to an existing treatment (ASTX727) works better for controlling advanced blood cancers. It will involve about 62 adults with specific aggressive forms of myeloproliferative neoplasms (MPNs) that have progressed. T…

This study is testing a two-part treatment for myelofibrosis, a serious bone marrow disease. First, patients take a JAK inhibitor drug. Then, they receive a stem cell transplant from a partially matched donor. The main goal is to see if using the drug for a longer time—before, du…

This study is testing if adding a drug called ruxolitinib to standard treatment can make stem cell transplants safer and more effective for older adults with myelofibrosis or related blood cancers. The main goal is to prevent a dangerous complication where the donor cells attack …

This study is creating a national patient registry in Germany to track how people with myelofibrosis (a bone marrow cancer) and anemia are treated in real-world clinics. It will follow 200 patients for up to three years to document which treatments they receive, in what order, an…

This is a long-term observational study designed to better understand a group of rare, chronic blood cancers called myeloproliferative neoplasms (MPNs). It will follow 5,000 adults in the U.S. for 5-10 years, collecting health records and patient surveys to track symptoms, treatm…